Aurobindo Pharma Wins Double USFDA Nod, Unlocks Billion-Dollar Diabetes Market With Dapagliflozin Portfolio

Admin Apr 07, 2026 38 Views

Aurobindo Pharma has received final USFDA approvals to market Dapagliflozin Tablets (5 mg and 10 mg) and Dapagliflozin with Metformin Hydrochloride Extended-Release Tablets in multiple strengths. With eligibility for 180 days of shared generic exclusivity, the company is set to tap into a multibillion-dollar diabetes care market.

Aurobindo Pharma Limited, headquartered in Hyderabad, has announced two significant regulatory milestones. The approvals cover standalone Dapagliflozin tablets and combination formulations with Metformin Hydrochloride, positioning the company strongly in the global anti-diabetic segment.

Market Impact And Exclusivity

The standalone Dapagliflozin tablets, bioequivalent to AstraZeneca’s Farxiga, represent a market size of approximately US$ 10.2 billion for the twelve months ending February 2026. The combination product, equivalent to AstraZeneca’s Xigduo XR, has an estimated market size of US$ 514 million. As one of the first ANDA applicants with paragraph IV certification, Aurobindo Pharma is eligible for 180 days of shared generic drug exclusivity, a critical advantage in capturing early market share.

Manufacturing And Launch Plans

Both products will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma. The company has confirmed immediate launch plans, leveraging its extensive manufacturing and packaging facilities approved by global regulators including USFDA, UK MHRA, and Japan PMDA.

Therapeutic Significance

Dapagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus. The combination with Metformin Hydrochloride further expands treatment options for patients requiring dual therapy, reinforcing Aurobindo’s commitment to addressing chronic conditions with affordable generics.

Key Highlights

USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg
USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in four strengths
Estimated market size: US$ 10.2 billion (Dapagliflozin) and US$ 514 million (combination)
Eligibility for 180 days of shared generic exclusivity
Immediate launch from Unit-IV of APL Healthcare Limited

Sources: Aurobindo Pharma press releases

Stay Ahead – Explore Now! Ram Charan's Peddi Release Preponed to March 26, 2026: Director Buchhi Babu Sana Shares Key Updates